[EN] PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS DANS LE TRAITEMENT DU CANCER
申请人:MERCK PATENT GMBH
公开号:WO2016128140A1
公开(公告)日:2016-08-18
Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.
Electron Impact Induced Fragmentation of Aromatic Alkoxyimines II [5]. Formation and Transformation of Heterocyclic Radical Cations in the Gas Phase a
作者:Alexander Kaiser、Klaus K. Mayer、Andreas Sellmer、Wolfgang Wiegrebe
DOI:10.1007/s00706-002-0485-8
日期:2003.2.1
The molecular ion 1 of N -( n -propoxy)benzaldimine I rearranges by an 1,5-H-shift to the δ-distonic ion 2 which subsequently cyclizes to the α-distonic ion 3 . Homolytic cleavage of the N–O bond in 3 results in the δ-distonic ion 4 which expels CH2O leading to the β-distonic ion 5 . Ion 5 is also formed from the molecular ions of tetrahydrooxazines II and III and from M+• of phenylazetidine IVa
分子离子 1 的 ñ - ( ñ -丙氧基)benzaldimine 我 由1,5- H-转移到δ-distonic离子重新排列 2 ,其随后环化成α-distonic离子 3 。N-O键在 3 中的均质裂解 导致δ-distonic离子 4 排出CH 2 O导致β-distonic离子 5 。离子 5 也由四氢恶嗪 II 和 III 的分子离子 以及 苯基 氮杂环丁烷IVa的 M +•形成 。在随后的步骤中,离子 5 环 化为 N- 质子化的3,4-二氢异喹啉鎓离子 6 。描述了 II – IV 及其衍生物的合成 。
GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
申请人:NEUROCRINE BIOSCIENCES, INC.
公开号:EP1255738B1
公开(公告)日:2012-03-07
PYRIMIDINE DERIVATIVES
申请人:Merck Patent GmbH
公开号:US20180118721A1
公开(公告)日:2018-05-03
Compounds of Formula I or II
in which R1, X1 and X2 have the meanings indicated in claim
1
, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.
Easy access to constrained peptidomimetics and 2,2-disubstituted azetidines by the unexpected reactivity profile of α-lithiated N-Boc-azetidines
作者:Giovanna Parisi、Emanuela Capitanelli、Antonella Pierro、Giuseppe Romanazzi、Guy J. Clarkson、Leonardo Degennaro、Renzo Luisi
DOI:10.1039/c5cc06323j
日期:——
The unprecedented reactivity profile of lithiatedN-Boc-2-arylazetidines gave access either to new azetidine-based peptidomimetics or to the regioselective functionalization of the azetidine ring.